IHAM
JAZZ icon

Integral Health Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Integral Health Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,874
Closed -$3.26M – 72
2022
Q2 		$3.26M Sell
20,874
-14,126
-40% -$2.17M 0.67% 48
2022
Q1 		$5.45M Buy
+35,000
New +$5.08M 1.42% 29

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Integral Health Asset Management's JAZZ Position: Q3 2022 in Review

Integral Health Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 20,874 shares — an estimated $3.26M sold.

Integral Health Asset Management first reported a position in JAZZ in Q1 2022 and held it in 2 quarters. The position peaked at $5.45M in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Integral Health Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Integral Health Asset Management sold 20,874 Jazz Pharmaceuticals shares in Q3 2022, an estimated $3.26M.
  • Integral Health Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Integral Health Asset Management's Jazz Pharmaceuticals position peaked at $5.45M in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.